Quantcast

Latest Adalimumab Stories

2010-11-03 07:00:00

BURLINGTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of psoriatic arthritis, Abbott/Eisai's Humira has emerged as the market leader, garnering sales of more than $500 million in 2009 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Despite Humira's later entry to the psoriatic arthritis market behind that of...

2010-10-20 06:44:00

ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2010. Diluted earnings per share, excluding specified items, were $1.05, reflecting 14.1 percent growth, at the high end of Abbott's previously issued guidance range of $1.03 to $1.05. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.57, primarily reflecting costs associated with recently announced...

2010-10-14 08:00:00

BURLINGTON, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, between 2010 and 2013, surveyed European rheumatologists expect well-established TNF-alpha inhibitors to lose considerable patient share to newer agents in this drug class, most notably Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi and UCB/Otsuka's Cimzia. The increased use of newer agents such as...

2010-10-05 07:00:00

BURLINGTON, Mass., Oct. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists and dermatologists expect they will increase their use of Centocor Ortho Biotech's Simponi as a first-line disease-modifying antirheumatic drug (DMARD) by the end of 2014 for the treatment of psoriatic arthritis. According to the new report entitled Treatment Algorithms in Psoriatic Arthritis,...

2010-10-05 07:00:00

BURLINGTON, Mass., Oct. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the ulcerative colitis drug market, modest growth of $800 million though 2019 will be driven by the uptake of Abbott/Eisai's Humira, Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen's Simponi and Millennium's vedolizumab in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The...

2010-09-29 08:30:00

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic...

2010-09-22 07:00:00

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense. According to the new report entitled Treatment Algorithms in Psoriasis, dermatologists'...

2010-09-16 12:12:00

SAN DIEGO, Sept. 16 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira® and...

2010-09-15 11:55:00

BURLINGTON, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis (RA), 44 percent of surveyed rheumatologists who expect to prescribe Genmab/GlaxoSmithKline's Arzerra say they will prescribe Arzerra before Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan. Only 22 percent of surveyed rheumatologists who do not expect to prescribe Arzerra...

2010-08-31 07:00:00

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related